Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Research & Development (2017 - 2025)

Purple Biotech has reported Research & Development over the past 6 years, most recently at $4.8 million for Q4 2022.

  • Quarterly Research & Development rose 48.54% to $4.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $16.3 million through Dec 2022, up 37.99% year-over-year, with the annual reading at $3.7 million for FY2025, 51.04% down from the prior year.
  • Research & Development was $4.8 million for Q4 2022 at Purple Biotech, up from $3.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $6.0 million in Q1 2022 and troughed at $986000.0 in Q4 2019.
  • The 5-year median for Research & Development is $3.2 million (2021), against an average of $3.3 million.
  • Year-over-year, Research & Development plummeted 59.36% in 2019 and then skyrocketed 338.54% in 2020.
  • A 5-year view of Research & Development shows it stood at $2.4 million in 2018, then plummeted by 59.36% to $986000.0 in 2019, then skyrocketed by 338.54% to $4.3 million in 2020, then dropped by 24.95% to $3.2 million in 2021, then skyrocketed by 48.54% to $4.8 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Research & Development are $4.8 million (Q4 2022), $3.5 million (Q3 2022), and $2.1 million (Q2 2022).